October 2, 2023 02:10 PM EDT
Pharma
FDA+

Bio­gen nabs FDA ap­proval for its biosim­i­lar of arthri­tis and Covid-19 drug Actem­ra

Katherine Lewin

News Reporter

Bio­gen scored an ap­proval from the FDA for its biosim­i­lar of Roche’s treat­ment Actem­ra on Fri­day, mark­ing the first biosim­i­lar of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Benev­o­len­tAI’s co-founder is back. Here’s how he plans a turn­around at the AI com­pa­ny dur­ing a ‘piv­otal time’

Biotech in­dus­try wor­ries over po­ten­tial for RFK Jr. al­ly as FDA pick

Ei­sai slash­es Leqem­bi sales fore­cast by al­most $100M

GSK leaves biotech trade group BIO

Am­gen and As­traZeneca share pos­i­tive re­sults in chron­ic rhi­nos­i­nusi­tis

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times